Cargando…
Acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient
This study reports the first patient treatment for cutaneous malignant melanoma using a linear accelerator-based boron neutron capture therapy (BNCT) system. A single-center open-label phase I clinical trial had been conducted using the system since November 2019. A patient with a localized node-neg...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613025/ https://www.ncbi.nlm.nih.gov/pubmed/37901311 http://dx.doi.org/10.3389/fonc.2023.1272507 |
_version_ | 1785128735267094528 |
---|---|
author | Igaki, Hiroshi Nakamura, Satoshi Yamazaki, Naoya Kaneda, Tomoya Takemori, Mihiro Kashihara, Tairo Murakami, Naoya Namikawa, Kenjiro Nakaichi, Tetsu Okamoto, Hiroyuki Iijima, Kotaro Chiba, Takahito Nakayama, Hiroki Nagao, Ayaka Sakuramachi, Madoka Takahashi, Kana Inaba, Koji Okuma, Kae Nakayama, Yuko Shimada, Kazuaki Nakagama, Hitoshi Itami, Jun |
author_facet | Igaki, Hiroshi Nakamura, Satoshi Yamazaki, Naoya Kaneda, Tomoya Takemori, Mihiro Kashihara, Tairo Murakami, Naoya Namikawa, Kenjiro Nakaichi, Tetsu Okamoto, Hiroyuki Iijima, Kotaro Chiba, Takahito Nakayama, Hiroki Nagao, Ayaka Sakuramachi, Madoka Takahashi, Kana Inaba, Koji Okuma, Kae Nakayama, Yuko Shimada, Kazuaki Nakagama, Hitoshi Itami, Jun |
author_sort | Igaki, Hiroshi |
collection | PubMed |
description | This study reports the first patient treatment for cutaneous malignant melanoma using a linear accelerator-based boron neutron capture therapy (BNCT) system. A single-center open-label phase I clinical trial had been conducted using the system since November 2019. A patient with a localized node-negative acral malignant melanoma and the largest diameter of the tumor ≤ 15 cm who refused primary surgery and chemotherapy was enrolled. After administering boronophenylalanine (BPA), a single treatment of BNCT with the maximum dose of 18 Gy-Eq delivered to the skin was performed. The safety and efficacy of the accelerator-based BNCT system for treating localized cutaneous malignant melanoma were evaluated. The first patient with cutaneous malignant melanoma in situ on the second finger of the left hand did not develop dose-limiting toxicity in the clinical trial. After BNCT, the treatment efficacy was gradually observed, and the patient achieved PR within 6 months and CR within 12 months. Moreover, during the follow-up period of 12 months after BNCT, the patient did not exhibit a recurrence without any treatment-related grade 2 or higher adverse events. Although grade 1 adverse events of dermatitis, dry skin, skin hyperpigmentation, edema, nausea, and aching pain were noted in the patient, those adverse events were relieved without any treatment. This case report shows that the accelerator-based BNCT may become a promising treatment modality for cutaneous malignant melanoma. We expect further clinical trials to reveal the efficacy and safety of the accelerator-based BNCT for cutaneous malignant melanoma. |
format | Online Article Text |
id | pubmed-10613025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106130252023-10-29 Acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient Igaki, Hiroshi Nakamura, Satoshi Yamazaki, Naoya Kaneda, Tomoya Takemori, Mihiro Kashihara, Tairo Murakami, Naoya Namikawa, Kenjiro Nakaichi, Tetsu Okamoto, Hiroyuki Iijima, Kotaro Chiba, Takahito Nakayama, Hiroki Nagao, Ayaka Sakuramachi, Madoka Takahashi, Kana Inaba, Koji Okuma, Kae Nakayama, Yuko Shimada, Kazuaki Nakagama, Hitoshi Itami, Jun Front Oncol Oncology This study reports the first patient treatment for cutaneous malignant melanoma using a linear accelerator-based boron neutron capture therapy (BNCT) system. A single-center open-label phase I clinical trial had been conducted using the system since November 2019. A patient with a localized node-negative acral malignant melanoma and the largest diameter of the tumor ≤ 15 cm who refused primary surgery and chemotherapy was enrolled. After administering boronophenylalanine (BPA), a single treatment of BNCT with the maximum dose of 18 Gy-Eq delivered to the skin was performed. The safety and efficacy of the accelerator-based BNCT system for treating localized cutaneous malignant melanoma were evaluated. The first patient with cutaneous malignant melanoma in situ on the second finger of the left hand did not develop dose-limiting toxicity in the clinical trial. After BNCT, the treatment efficacy was gradually observed, and the patient achieved PR within 6 months and CR within 12 months. Moreover, during the follow-up period of 12 months after BNCT, the patient did not exhibit a recurrence without any treatment-related grade 2 or higher adverse events. Although grade 1 adverse events of dermatitis, dry skin, skin hyperpigmentation, edema, nausea, and aching pain were noted in the patient, those adverse events were relieved without any treatment. This case report shows that the accelerator-based BNCT may become a promising treatment modality for cutaneous malignant melanoma. We expect further clinical trials to reveal the efficacy and safety of the accelerator-based BNCT for cutaneous malignant melanoma. Frontiers Media S.A. 2023-10-13 /pmc/articles/PMC10613025/ /pubmed/37901311 http://dx.doi.org/10.3389/fonc.2023.1272507 Text en Copyright © 2023 Igaki, Nakamura, Yamazaki, Kaneda, Takemori, Kashihara, Murakami, Namikawa, Nakaichi, Okamoto, Iijima, Chiba, Nakayama, Nagao, Sakuramachi, Takahashi, Inaba, Okuma, Nakayama, Shimada, Nakagama and Itami https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Igaki, Hiroshi Nakamura, Satoshi Yamazaki, Naoya Kaneda, Tomoya Takemori, Mihiro Kashihara, Tairo Murakami, Naoya Namikawa, Kenjiro Nakaichi, Tetsu Okamoto, Hiroyuki Iijima, Kotaro Chiba, Takahito Nakayama, Hiroki Nagao, Ayaka Sakuramachi, Madoka Takahashi, Kana Inaba, Koji Okuma, Kae Nakayama, Yuko Shimada, Kazuaki Nakagama, Hitoshi Itami, Jun Acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient |
title | Acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient |
title_full | Acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient |
title_fullStr | Acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient |
title_full_unstemmed | Acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient |
title_short | Acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient |
title_sort | acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613025/ https://www.ncbi.nlm.nih.gov/pubmed/37901311 http://dx.doi.org/10.3389/fonc.2023.1272507 |
work_keys_str_mv | AT igakihiroshi acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT nakamurasatoshi acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT yamazakinaoya acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT kanedatomoya acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT takemorimihiro acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT kashiharatairo acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT murakaminaoya acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT namikawakenjiro acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT nakaichitetsu acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT okamotohiroyuki acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT iijimakotaro acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT chibatakahito acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT nakayamahiroki acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT nagaoayaka acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT sakuramachimadoka acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT takahashikana acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT inabakoji acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT okumakae acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT nakayamayuko acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT shimadakazuaki acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT nakagamahitoshi acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient AT itamijun acralcutaneousmalignantmelanomatreatedwithlinearacceleratorbasedboronneutroncapturetherapysystemacasereportoffirstpatient |